Health-related quality of life in women with breast cancer: a review of measures.

Autor: Salas M; Epidemiology, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Inc., 211 Mount Airy Road, 1A-453, Basking Ridge, NJ, 07920, USA. msalas@dsi.com.; CCEB/CPeRT, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. msalas@dsi.com., Mordin M; RTI Health Solutions, Ann Arbor, MI, USA., Castro C; RTI Health Solutions, Research Triangle Park, NC, USA., Islam Z; Epidemiology, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Inc., 211 Mount Airy Road, 1A-453, Basking Ridge, NJ, 07920, USA., Tu N; Epidemiology, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Inc., 211 Mount Airy Road, 1A-453, Basking Ridge, NJ, 07920, USA., Hackshaw MD; Epidemiology, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Inc., 211 Mount Airy Road, 1A-453, Basking Ridge, NJ, 07920, USA.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2022 Jan 15; Vol. 22 (1), pp. 66. Date of Electronic Publication: 2022 Jan 15.
DOI: 10.1186/s12885-021-09157-w
Abstrakt: Background: To identify and describe the breast cancer-specific health-related quality of life (HRQoL) instruments with evidence of validation in the breast cancer population for potential use in patients treated for breast cancer (excluding surgery).
Methods: We conducted a systematic literature review using PubMed, Embase, and PsycINFO databases to identify articles that contain psychometric properties of HRQoL instruments used in patients with breast cancer. Relevant literature from January 1, 2009, to August 19, 2019, was searched. Articles published in English that reported psychometric properties (reliability, validity) of HRQoL instruments were identified.
Results: The database search yielded 613 unique records; 131 full-text articles were reviewed; 80 articles presented psychometric data for instruments used in breast cancer (including generic measures). This article reviews the 33 full articles describing psychometric properties of breast cancer-specific HRQoL instruments: EORTC QLQ-C30, EORTC QLQ-BR23, FACT-B, FBSI, NFBSI-16, YW-BCI36, BCSS, QuEST-Br, QLICP-BR, INA-BCHRQoL, and two newly developed unnamed measures, one by Deshpande and colleagues (for use in India) and one by Vanlemmens and colleagues (for use among young women and their partners). The articles that described the EORTC QLQ-C30, QLQ-BR23, and FACT-B centered on validating translations, providing additional support for content validity, and demonstrating acceptability of electronic patient-reported outcome administration. Psychometric properties of the measures were acceptable. Several new measures have been developed in Asia with an emphasis on development on cultural relevance/sensitivity. Others focused on specific populations (i.e., young women with breast cancer).
Conclusions: Historically, there have been limited options for validated measures to assess HRQoL of patients with breast cancer. A number of new measures have been developed and validated, offering promising options for assessing HRQoL in this patient population. This review supports the reliability and validity of the EORTC QLQ-C30 and FACT-B; new translations and electronic versions of these measures further support their use for this population.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje